Navigation Links
GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
Date:8/11/2008

ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its financial results and provided an operational update for the six months ended June 30, 2008.

Financial Results for the Three Months and Six Months Ended June 30, 2008

The Company recorded a net loss of $1,284,352 for the three months ended June 30, 2008, compared to $1,333,126 for the same period in 2007. For the six months ended June 30, 2008, the Company's net loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of June 30, 2008, the Company reported cash balances totaling $3,133,839.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our six month financial results, including our operational expenses and cash position. Our operational expenses are minimal for a company of our size and stage of clinical trial development. We are particularly pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2 preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the therapeutic trial in HIV infected and drug-treated humans."

Dr. McN
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeoVax Further Strengthens Management Team
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
4. Genaera Corporation Announces Second Quarter Financial Results
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
8. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... members will be attending Pharma Ed Resources upcoming educational seminar and training ... industry leading speakers, this timely conference will provide Updates & Case Studies on ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... 500th patient was supported with the,Berlin Heart EXCOR(R) Pediatric ... the first implantation of the device in 1990. The,patient, ... Memorial,Hospital in Chicago and has been successfully transplanted in ... been diagnosed a few weeks after birth with left,ventricular ...
... ISELIN, N.J., May 28 SyntheMed, Inc. (OTC ... the development and commercialization of anti-adhesion products, announced ... film for the reduction of adhesions following cardiac ... Goods Administration for use in all patients who ...
... Quest Diagnostics scientists will present results of three ... diagnosis and treatment of chronic myeloid leukemia (CML) and ... American Society of Clinical Oncology (ASCO), scheduled for May ... Incorporated (NYSE: DGX ) is the world,s ...
Cached Biology Technology:500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R) 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 2Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 3Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 4Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting 5
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... mixing it with sugar, making thick jams that last ... Institute of Standards and Technology (NIST) have discovered* a ... the life of many things including vaccines, food and ... addition to jams, sugars are often used to preserve ...
... unlucky encounter with a crab,s pinchers, consider that the ... times harder than acrylic glass and extremely fracture resistant, ... the U.S. West Coast may have had close encounters ... in a paper published online in advance of regular ...
... not just the climate that is struggling with what humans ... the pressure as well, according to Professor Greg Gibson,s recently ... a Clash Between Our Genes and Modern Life Is Making ... Sciences, suggests the increased rates of diseases such as diabetes, ...
Cached Biology News:Probing and controlling 'molecular rattling' may mean better preservatives 2Crab claws pack strengthening bromide-rich biomaterial 2'It takes a genome: How a clash between our genes and modern life is making us sick' 2
DTT 50 l...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: